FOXO4-DRI is a synthetic D-amino acid retro-inverso peptide studied in preclinical senolytic research for its role in FOXO4-p53 interaction disruption and senescent cell apoptosis pathways.
FOXO4-DRI is a synthetic peptide built using D-amino acid retro-inverso (DRI) design, meaning its amino acid sequence is reversed and composed of D-isomer residues rather than the naturally occurring L-isomers. CAS: 1798709-82-6. This design mirrors the side-chain topology of the original L-peptide closely enough to preserve target binding, while resisting degradation by proteolytic enzymes that recognize only L-amino acid backbones — a property studied for extending compound stability in in-vitro research applications.
FOXO4-DRI is studied for its role in disrupting the protein-protein interaction between FOXO4 and p53 within senescent cells. Senescent cells — cells that have permanently exited the cell cycle but resist apoptosis — accumulate FOXO4 in a complex that sequesters p53 in the nucleus, blocking its normal apoptotic signaling. By competitively disrupting this FOXO4-p53 interaction, FOXO4-DRI has been studied for freeing p53 to translocate to the mitochondria and initiate cell-intrinsic apoptosis selectively in senescent cells, a mechanism of interest in senolytic (senescent cell-clearing) research.
NuvoTide's FOXO4-DRI is supplied as a lyophilized powder, HPLC verified to ≥99% purity, and should be stored at -20°C prior to reconstitution. All NuvoTide Research products, including FOXO4-DRI, are supplied strictly for in-vitro laboratory research purposes and are not intended for human or veterinary use, and are not FDA-approved.
For in-vitro research use only. Not for human or veterinary use.